Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

GF25 Anti-VEGF (Ab-3) Mouse mAb (14-124)

This Anti-VEGF (Ab-3) Mouse mAb (14-124) is validated for use in Immunoblotting, Paraffin Sections for the detection of VEGF (Ab-3).

Anti-VEGF (Ab-3) Mouse mAb (14-124) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-Vascular Permeability Factor, Anti-VPF, Anti-Vascular Endothelial Growth Factor

GF25
  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Species ReactivityHostAntibody Type
HMMonoclonal Antibody
Description
Overview

This product has been discontinued.



Recognizes the ~31-50 kDa VEGF121, VEGF165, VEGF189, and VEGF206 proteins.
Catalogue NumberGF25
Brand Family Calbiochem®
SynonymsAnti-Vascular Permeability Factor, Anti-VPF, Anti-Vascular Endothelial Growth Factor
References
ReferencesKlagsbrun, M. and Soker, S., 1993. Current Biology 3 699.
Senger, D., et al. 1993. Cancer and Metastasis Reviews In Press.
Brown, L., et al. 1992. Kidney International 42, 1457.
Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
Product Information
FormLiquid
FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
Negative controlNormal brain
Positive controlRecombinant VEGF protein or fetal kidney
Preservative≤0.1% sodium azide
Applications
Application ReferencesImmunoblotting Uthoff, S.M.S., et al. 2002. Int. J. Cancer 101, 32. Sauter, E.R., et al. 1999. Clin. Cancer Res. 5, 775.
Key Applications Immunoblotting (Western Blotting)
Paraffin Sections
Application NotesImmunoblotting (0.5 µg/ml, see comments and application references)
Paraffin Sections (5.0 µg/ml, trypsin or pressure cooker pre-treatment required)
Application CommentsFor immunoblotting, include 1% BSA with the primary antibody. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogena synthetic peptide corresponding to amino acids from the N-terminus of human VEGF₁₆₅
ImmunogenHuman
Clone14-124
HostMouse
IsotypeIgG₁
Species Reactivity
  • Human
Antibody TypeMonoclonal Antibody
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Blue Ice Only
Toxicity Standard Handling
Storage +2°C to +8°C
Do not freeze Yes
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
GF25 0

Documentation

Anti-VEGF (Ab-3) Mouse mAb (14-124) Certificates of Analysis

TitleLot Number
GF25

References

Reference overview
Klagsbrun, M. and Soker, S., 1993. Current Biology 3 699.
Senger, D., et al. 1993. Cancer and Metastasis Reviews In Press.
Brown, L., et al. 1992. Kidney International 42, 1457.
Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.

Citations

Title
  • Sonja M.S. Uthoff, et al. (2002) VEGF Isoforms and Mutations in Human Colorectal Cancer. International Journal of Cancer 101, 32-36.
  • Edward R. Sauter, et al. (1999) Vascular Endothelial Growth Factor Is a Marker of Tumor Invasion and Metastasis in Squamous Cell Carcinomas of the Head and Neck. Clinical Cancer Research 5, 775-782.
    		•
    Data Sheet

    Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

    Revision23-August-2007 RFH
    SynonymsAnti-Vascular Permeability Factor, Anti-VPF, Anti-Vascular Endothelial Growth Factor
    ApplicationImmunoblotting (0.5 µg/ml, see comments and application references)
    Paraffin Sections (5.0 µg/ml, trypsin or pressure cooker pre-treatment required)
    DescriptionPurified mouse monoclonal antibody generated by immunizing Balb/c mice with the specified immunogen and fusing splenocytes with mouse SP2/0 cells. Recognizes the ~31-50 kDa VEGF121, VEGF165, VEGF189, and VEGF206 proteins.
    BackgroundVascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a secreted heparin binding cytokine expressed in tumor and animal cells. VEGF has been implicated in the control of angiogenesis due to its selective mitogenic stimulation of vascular endothelial cells and enhancement of vascular permeability. Other effects of VEGF on vascular endothelial cells include; increasing intracellular calcium, stimulating inositol triphosphate formation, induction of von Willebrand factor release, and stimulating tissue factor expression. VEGF is a ~46 kDa dimer of two identical disulfide-linked subunits existing in four molecular species; 121, 165, 189, and 206 amino acid residues long.
    HostMouse
    Immunogen speciesHuman
    Immunogena synthetic peptide corresponding to amino acids from the N-terminus of human VEGF₁₆₅
    Clone14-124
    IsotypeIgG₁
    Specieshuman
    Positive controlRecombinant VEGF protein or fetal kidney
    Negative controlNormal brain
    FormLiquid
    FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
    Concentration Label Please refer to vial label for lot-specific concentration
    Preservative≤0.1% sodium azide
    CommentsFor immunoblotting, include 1% BSA with the primary antibody. Antibody should be titrated for optimal results in individual systems.
    Storage +2°C to +8°C
    Do Not Freeze Yes
    Toxicity Standard Handling
    ReferencesKlagsbrun, M. and Soker, S., 1993. Current Biology 3 699.
    Senger, D., et al. 1993. Cancer and Metastasis Reviews In Press.
    Brown, L., et al. 1992. Kidney International 42, 1457.
    Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
    Citation
  • Sonja M.S. Uthoff, et al. (2002) VEGF Isoforms and Mutations in Human Colorectal Cancer. International Journal of Cancer 101, 32-36.
  • Edward R. Sauter, et al. (1999) Vascular Endothelial Growth Factor Is a Marker of Tumor Invasion and Metastasis in Squamous Cell Carcinomas of the Head and Neck. Clinical Cancer Research 5, 775-782.
    		•
    Application referencesImmunoblotting Uthoff, S.M.S., et al. 2002. Int. J. Cancer 101, 32. Sauter, E.R., et al. 1999. Clin. Cancer Res. 5, 775.